Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00035958

Recruitment Status : Terminated (Incorporating the recommendations of the NIH-formed DSMB in the study procedures would make the project budget over the limit for this funding mechanism.)

First Posted : May 8, 2002

Last Update Posted : August 1, 2013

Sponsor:

Collaborators:

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Immunex Corporation

Information provided by:

Children's Hospital Medical Center, Cincinnati

Study Description

Brief Summary:

Juvenile dermatomyositis (JDMS) is one of the most serious of the childhood rheumatic diseases. The theory behind this trial is that early introduction of etanercept or methotrexate will prove to be effective in the treatment of JDMS. Pretreatment muscle biopsies, we believe there will be abnormalities in the blood vessels that will be correlated with worse physical strength and daily functional ability. The long-term goal is to improve the treatment of this serious childhood onset rheumatic disease and to better understand the pathogenic mechanism for the development of the vasculopathy (disorder of blood vessels) of JDMS. Identification of the specific mechanism of the vasculopathy may allow for the rational introduction of biologic treatments focused on vascular growth.

Condition or disease	Intervention/treatment	Phase
Dermatomyositis	Drug: Prednisone Drug: Methotrexate Drug: Etanercept	Phase 2 Phase 3

Detailed Description:

The mortality of JDMS is 3-39% with over 40% of patients demonstrating long-term disability. Current first line therapy is high-dose corticosteroids with the attendant significant drug-related toxicity. Over 30% of JDMS patients fail to respond adequately to steroids and require additional immunosuppression, none of which have been tested in prospective, randomized, controlled trials. The unique occlusive vasculopathy in JDMS is critical in the pathogenesis and predictive of prognosis but poorly understood. Elevated levels of tumor necrosis factor (TNF) alpha have been shown to be present in JDMS and are associated with a more severe and chronic course.

Seventy-five children with definite JDMS will be enrolled in a 24-month prospective, randomized, multicentered trial comparing 3 treatments: oral prednisone (P), combination of oral prednisone and methotrexate (P/MTX), and combination of oral prednisone and etanercept (P/E). Primary response measures will be muscle strength and mean duration of steroid therapy. Secondary response variables are disability in daily function and height and weight growth velocity (steroid toxicity measures). The combination of P/E will be tested and compared to both P alone and the combination of P/MTX after 3, 6, 12, 18, and 24 months of treatment. In addition, the combination of P/MTX will be compared to P alone after 3, 6, 12, 18, and 24 months of treatment. In pretreatment muscle biopsies, proangiogenic factors (such as vascular endothelial cell growth factor and basic fibroblast growth factor), angiostatic factors (such as angiostatin and endostatin), and vascular morphology (vessel number, width, length and area) will be quantified and tested for ability to predict muscle strength and functional ability 3, 6, 12, 18, and 24 months later.

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	75 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis
Study Start Date :	August 2002
Actual Primary Completion Date :	August 2002
Actual Study Completion Date :	August 2002

Resource links provided by the National Library of Medicine

Genetic and Rare Diseases Information Center resources: Dermatomyositis Juvenile Dermatomyositis Polymyositis Idiopathic Inflammatory Myopathy

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	4 Years to 16 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria at the time of enrollment:

Definite or probable diagnosis of JDMS by the criteria of Bohan and Peter
No prior systemic steroid treatment for JDMS
If able to become pregnant (females) or impregnate (males) and are sexually active, then must have negative serum pregnancy test at baseline and be utilizing effective form of birth control
Patient and/or parent or legal guardian must be willing to sign consent and assent forms

Exclusion criteria at the time of enrollment:

History of chronic or recurrent infections sufficient to preclude the use of etanercept
Prior treatment with specific TNF-blocking agents
Demonstration of cutaneous or gastrointestinal (GI) ulceration at the time of diagnosis
JDMS-related pulmonary disease at time of diagnosis (interstitial lung disease or aspiration pneumonia confirmed by radiograph)
JDMS-related cardiomyopathy (echocardiogram confirmation)
Any uncontrolled, clinically significant pre-existent systemic disease (hepatic, renal, neurological, endocrine, cardiac, gastrointestinal, or hematologic disease) within 24 weeks of start of study
Known HIV, hepatitis B surface antigen not related to vaccination, or hepatitis C antibody positivity
Pregnant or nursing female
Any of the following laboratory abnormalities at baseline: platelet count < 100,000/cmm, total white cell count of < 3000 cells/cmm, neutrophils < 1000 cells/cmm, serum bilirubin > 2 times upper limit of normal, estimated creatinine clearance of < 90 mL/min/1.73 M2 BSA estimated by formula for males age 2 to <13 (0.55 X ht in cms/serum creatinine), age 13-18 (0.7 X ht in cms/serum creatinine) and females age 2-18 (0.55 X ht in cms/serum creatinine)
Received live virus vaccination within 3 months prior to study entry (contraindication for MTX or etanercept therapy)
Past or current substance abuse or psychiatric history that would interfere with ability to give informed consent or comply with study requirements or physician instructions

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00035958

Locations


United States, Ohio
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, United States, 45229

Sponsors and Collaborators

Children's Hospital Medical Center, Cincinnati

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Immunex Corporation

Investigators


Principal Investigator:	Daniel J. Lovell, MD, MPH	Children's Hospital Medical Center, Cincinnati

More Information


Responsible Party:	Daniel J. Lovell, MD, MPH, Cincinnati Children's Hospital Medical Center
ClinicalTrials.gov Identifier:	NCT00035958 History of Changes
Other Study ID Numbers:	P60AR047784 ( U.S. NIH Grant/Contract ) P60AR047784 ( U.S. NIH Grant/Contract ) NIAMS-078
First Posted:	May 8, 2002 Key Record Dates
Last Update Posted:	August 1, 2013
Last Verified:	July 2013

Keywords provided by Children's Hospital Medical Center, Cincinnati:


Juvenile Dermatomyositis Pediatric Randomized Clinical Trial Pediatric Rheumatology

Additional relevant MeSH terms:


Dermatomyositis Polymyositis Myositis Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Connective Tissue Diseases Skin Diseases Methotrexate Etanercept Prednisone Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents	Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Nucleic Acid Synthesis Inhibitors Anti-Inflammatory Agents Glucocorticoids Hormones

To Top